Completed PHASE3 INTERVENTIONAL NCT00064623

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy

Sponsor: NeurogesX

Conditions HIV Infections Pain Peripheral Nervous System Diseases

Interventions Capsaicin Dermal Patch

Updated 6 times since 2017 Last updated: Mar 4, 2008 Started: Aug 31, 2003 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV Infections and Pain and is currently completed. NeurogesX leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeurogesX

Data source: NeurogesX

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Austin, United States , Baltimore, United States , Berkeley, United States , Boston, United States , Camden, United States , Chapel Hill, United States , Chicago, United States , Cleveland, United States , Dallas, United States and 22 more locations